ICONICC: Interventions for Convergence Insufficiency in Concussed Children

Sponsor
Mitchell Scheiman (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03908112
Collaborator
Ohio State University (Other), University of Alabama at Birmingham (Other), Marshall B. Ketchum University (Other), Stanford University (Other), Children's Hospital Medical Center, Cincinnati (Other), Children's Hospital of Philadelphia (Other), Boston Children's Hospital (Other), New Jersey Institute of Technology (Other)
264
8
3
48
33
0.7

Study Details

Study Description

Brief Summary

The ICONICC Study is a randomized controlled clinical trial designed to compare the proportion of successful treatment outcomes between children assigned to standard concussion care only, standard concussion care plus simple convergence procedures, or standard concussion care plus office-based vergence/accommodative therapy in children aged 11 to 17 years with symptomatic post-concussion syndrome. Children with post-concussion syndrome (4-12 weeks post-concussion injury) and symptomatic CI will be randomized to a 12-week treatment program of either standard concussion care (SC), SC plus simple convergence procedures (SC+), or SC plus office-based vergence/accommodative therapy SC+OBVAT (1:1:1 ratio).

The study will also compare the effect of treatment on clinical measures of both accommodation and vergence, symptom level/burden, health-related quality of life, clinical measures of saccadic eye movement, and objective eye movement measurements of disparity vergence, saccadic function, and accommodative function. The attainment of objective eye movement measures provides an opportunity to understand the underlying neurophysiology of the vergence and accommodative systems. Objective eye movement recordings are powerful because of the rich foundation from primate single-cell recordings that show a direct correlation with vergence and accommodative parameters in the supraoculomotor area of midbrain2, 3 and the oculomotor vermis of the cerebellum.4, 5 Thus, a combined approach of acquiring both clinical vision function measures and objective eye movement recordings in children with PCS-CI may lead to better characterization of the oculomotor phenotype with subsequent improved and personalized therapeutic interventions.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Standard Community Concussion Care (SC)
  • Behavioral: SC plus Simple Convergence Exercises (SC+)
  • Behavioral: SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)
Phase 3

Detailed Description

Objectives:

A group of 264 diverse children, ages 11 to 17 years, with post-concussion syndrome (4-12 weeks post-concussion injury) and symptomatic CI will be enrolled from 6 sites from across the United States, will be randomized to 12 weeks of: 1) standard care (SC), 2) SC plus simple convergence exercises (SC+), and 3) SC plus office-based vergence/ accommodative therapy (SC+OBVAT).

Primary Objective: To compare the effectiveness of SC, SC+, SC plus office-based vergence/accommodative therapy for improving a composite outcome measure of clinical findings (near point of convergence and positive fusional vergence at near) in children 11-17 years of age with concussion-related CI after 12 weeks of treatment.

  • Secondary outcome measures

  • Objective measures of disparity vergence, accommodation, saccades, and smooth pursuit

  • Quality of life measures

  • Convergence Insufficiency Symptom Survey Concussion Version (CISS-CON)

  • PedsQL Version 4 For participants in any treatment group who not "successful" based on the composite score described above, additional/different treatment will be offered as an option after the primary outcome examination

Study Design

Study Type:
Interventional
Anticipated Enrollment :
264 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
To compare the effectiveness of SC, SC+, SC plus office-based vergence/accommodative therapy for improving a composite outcome measure of clinical findings (near point of convergence and positive fusional vergence at near) in children 11-17 years of age with concussion-related CI after 12 weeks of treatment.To compare the effectiveness of SC, SC+, SC plus office-based vergence/accommodative therapy for improving a composite outcome measure of clinical findings (near point of convergence and positive fusional vergence at near) in children 11-17 years of age with concussion-related CI after 12 weeks of treatment.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Participants will be masked to the treatment assignment and at follow-up examinations the examiners will be masked to the treatment group assignment. Investigators providing the therapy will be unmasked.
Primary Purpose:
Treatment
Official Title:
Interventions for Convergence Insufficiency in Concussed Children (ICONICC)
Anticipated Study Start Date :
Apr 1, 2021
Anticipated Primary Completion Date :
Mar 31, 2025
Anticipated Study Completion Date :
Mar 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard Community Concussion Care (SC)

Standard concussion care consists of physical and cognitive rest immediately following the injury for a brief period of time to allow symptoms to abate, followed by a gradual reintroduction of academic and physical activities, restricting activities at high risk for repeat brain injury (such as contact or collision sports) until a graded return to play protocol has been completed in a symptom-free manner.

Behavioral: Standard Community Concussion Care (SC)
temporary rest, gradual increase in activity, and return to school and sports. In some cases vestibular an balance therapy are necessary, aerobic exercises, medication, counseling.
Other Names:
  • Concussion treatment
  • Experimental: SC plus Simple Convergence Procedures (SC+)

    In addition to the treatment described for SC, participants in this group will be asked to work with the Brock String, which is a popular and simple therapy technique designed to improve convergence. A 3-phase, graded Brock String procedure has been developed for ICONICC.

    Behavioral: SC plus Simple Convergence Exercises (SC+)
    In addition to standard community care in this intervention the participants must perform convergence therapy every day at home
    Other Names:
  • Concussion care plus convergence exercises
  • Experimental: SC plus Office-based Vergence/Accommodative Therapy (SC+VAT)

    Office-based vergence accommodative therapy (OBVAT) is administered by a study certified therapist at weekly intervals (60-minute office visits with 55 minutes of therapy time), combined with procedures to practice at home for 15 minutes, 5 times per week.

    Behavioral: SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)
    In addition to standard community care in this intervention the participants must come to the office once a week for a 1-hour therapy session with a therapist. Office-based vergence/accommodative therapy is performed for 12 weeks with home reinforcement.
    Other Names:
  • vision therapy
  • Outcome Measures

    Primary Outcome Measures

    1. Composite of Measure of the Near Point of Convergence (NPC) and Positive Fusional Vergence at Near (PFV) [12 weeks]

      To evaluate successful treatment of CI, we will use a composite outcome classification of the 2 clinical outcome measures of NPC and PFV from baseline to the primary outcome examination. A participant will be defined as successfully treated if both criteria are met: 1) normal NPC (i.e., less than 6 cm) and 2) normal PFV (i.e., greater than 15 prism diopters base-out and passing Sheard's criterion

    Secondary Outcome Measures

    1. Peak velocity for 4° symmetrical convergence steps [12 weeks]

      The ISCAN RK-826PCI binocular tracking system (Burlington, MA) will be used used to objectively record horizontal vergence eye movements. Peak velocity will be measured with this instrument and a secondary outcome measures will be the change in peak velocity for 4° symmetrical convergence steps

    2. Time to peak velocity for 4° symmetrical convergence steps [12 Weeks]

      The ISCAN RK-826PCI binocular tracking system (Burlington, MA) will be used to objectively record horizontal vergence eye movements. Five parameters will be measured with this instrument and a secondary outcome measures will be the change in time to peak velocity for 4° symmetrical convergence steps

    3. Latency for 4° symmetrical convergence steps [12 weeks]

      The ISCAN RK-826PCI binocular tracking system (Burlington, MA) will be used used to objectively record horizontal vergence eye movements. Five parameters will be measured with this instrument and a secondary outcome measures will be the change in latency for 4° symmetrical convergence steps

    4. Response Amplitude for 4° symmetrical convergence steps [12 weeks]

      The ISCAN RK-826PCI binocular tracking system (Burlington, MA) will be used to objectively record horizontal vergence eye movements. Five parameters will be measured with this instrument and a secondary outcome measures will be the change in response amplitude for 4° symmetrical convergence steps

    5. Convergence Insufficiency Symptom Survey - Concussion Version (CISS-CON) [12 weeks]

      The change in the score on this survey will be a secondary outcome assessing symptoms

    6. Post-concussion Symptom Inventory (PCSI) [12 weeks]

      PCSI is a 26-item validated symptom inventory for children with concussion that identifies physical, cognitive, emotional and sleep factors following injury and is useful in capturing and tracking post-injury symptoms through recovery. The change in this score will be used as a secondary outcome measure.

    7. PedsQL (Pediatric Quality of Life Inventory) [12 Weeks]

      PedsQL (Pediatric Quality of Life Inventory) measures health-related quality of life (HRQOL) in children and adolescents. The change in this score will be used as a secondary outcome measure.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    11 Years to 17 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    ICONICC will enroll children of all races and will adhere to a policy of equitability. To be eligible to participate in ICONICC, the child must meet all of the following criteria:

    1. Medical diagnosis of concussion of at least 4 weeks and no longer than 12 weeks since known date of injury

    2. Age 11 to 17 years

    3. Gender - any

    4. CI Symptom Survey (CISS) score ≥ 16

    5. Exophoria at near at least 4∆ greater than at far

    6. Receded near point of convergence (NPC) of greater than 6 cm break

    7. Insufficient positive fusional vergence (PFV) at near (i.e., failing Sheard's criterion1 or PFV ≤15∆ base-out break)

    8. Best-corrected distance visual acuity of 20/25 or better in each eye

    9. Random dot stereopsis appreciation of 500 seconds of arc or better using the Randot Stereotest

    10. Willing to wear refractive correction for any of the following uncorrected refractive errors based on a cycloplegic refraction performed at the eligibility examination. (Correction must be worn for at least 2 weeks):

    • Myopia > -0.75 D spherical equivalent in either eye

    • Hyperopia > 2.00 D spherical equivalent in either eye

    • Anisometropia > 0.75D spherical equivalent or ≥ 1.50 D in any meridian

    • Astigmatism > 1.00 D in either eye

    1. Willing to discontinue BI prism or a plus add at near for duration of study (must discontinue at least 2 weeks before eligibility examination)

    2. Parent and child understand protocol and are willing to accept randomization

    3. Normal pupillary responses

    Exclusion Criteria:
    1. Any strabismus at distance

    2. Constant strabismus at near

    3. Limitation on versions/ductions due to restrictive or paretic strabismus

    4. Esophoria of ≥ 2∆ at distance

    5. Vertical heterophoria ≥ 2∆ at distance or near

    6. ≥ 2 line interocular difference in best-corrected visual acuity

    7. Manifest or latent nystagmus

    8. History of surgery or botulinum toxin for strabismus or any type of refractive surgery

    9. Previous diagnosis of CI by an eye care professional before concussion

    10. Diseases known to affect accommodation, vergence, or ocular motility such as multiple sclerosis, Graves orbitopathy, myasthenia gravis, diabetes mellitus, Parkinson's disease

    11. Inability to comprehend and/or perform any study-related, clinical vision function test

    12. Household member enrolled in present ICONICC study or treated within the past 6 months with any form of office-based vergence/accommodative therapy or home-based vergence therapy (e.g., computerized vergence therapy)

    13. Household member is an eye care professional, ophthalmic technician, ophthalmology or optometry resident or fellow, or optometry student

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Alabama Birmingham Birmingham Alabama United States 35233
    2 Marshall B. Ketchum University, Southern CA College of Optomwtry Fullerton California United States 92831
    3 Stanford University Medical Center Palo Alto California United States 94304
    4 Boston's Children's Hospital Boston Massachusetts United States 02453
    5 New Jersey Institute of Technology Newark New Jersey United States 07102
    6 Cincinnati Children's Hospital Medical Center Cincinnati Ohio United States 45229
    7 The Ohio State University College of Optometry Columbus Ohio United States 43210
    8 Salus University/Children's Hospital of Philadelphia Philadelphia Pennsylvania United States 19141

    Sponsors and Collaborators

    • Mitchell Scheiman
    • Ohio State University
    • University of Alabama at Birmingham
    • Marshall B. Ketchum University
    • Stanford University
    • Children's Hospital Medical Center, Cincinnati
    • Children's Hospital of Philadelphia
    • Boston Children's Hospital
    • New Jersey Institute of Technology

    Investigators

    • Study Chair: Mitchell Scheiman, OD, PhD, Salus University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mitchell Scheiman, Dean of Research, Salus University
    ClinicalTrials.gov Identifier:
    NCT03908112
    Other Study ID Numbers:
    • Salus 1003-2019
    First Posted:
    Apr 9, 2019
    Last Update Posted:
    Oct 23, 2020
    Last Verified:
    Oct 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Mitchell Scheiman, Dean of Research, Salus University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 23, 2020